Clinical Trial Update: To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years [Phase 2]

View source ↗

Summary

Phase 2 clinical trial to evaluate the safety and immunogenicity of a 15-valent HPV recombinant vaccine in Chinese people aged 9-45; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Genital Warts
• Human Papillomavirus Infection
• Human Papillomavirus-related Carcinoma
• Human Papillomavirus-related Intraepithelial Neoplasia

Drugs mentioned

• 15-valent HPV recombinant vaccine (HPV recombinant vaccine, 15-valent)

Snippet

Sponsor: Shanghai Bovax Biotechnology Co., Ltd. | Conditions: HPV Infection, HPV-Related Carcinoma | Phase 2 | Status: RECRUITING